
VET Cell Tech sp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
Vet Cell Tech is a veterinary biotech company from Poland that develops innovative stem cell-based therapies for dogs and cats. They utilize a proprietary stem cell technology platform to create effective treatments for common diseases in companion animals. The company focuses on ensuring high safety profiles and cost-effectiveness in their products.
Financials
Revenue history (in k)
Filing timeliness
2 of 3 financial statements were filed late (the longest delay 73 days for 2023).
- 202513/07/2026
- 202417/07/2025
- 202326/09/2024
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Veterinary therapies
- Cell products
- Stem cell banks
- iPSC cell lines
Websites
- vetcelltech.comVet Cell Tech - innowacyjne produkty oparte na komórkach macierzystych dla psów i kotów.WordPress 7.1Yoast SEOApache
Authorized Representatives
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Marcin Krzysztof Liwoch age 53 | 194 | $2,620.21 | 15.336% |
Marcin Marek Majka age 54 | 450 | $6,077.80 | 35.5731% |
Konrad Grzegorz Szczukiewicz age 37 | 188 | $2,539.17 | 14.8617% |
Piotr Antoni Sznelewski age 57 | 303 | $4,092.38 | 23.9526% |
Others | 130 | $1,755.81 | 10.2766% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2023-04-12.
56 1090 2590 0000 0001 5345 1825
Debt
No entries in the National Debtors Register (KRZ).
Public aid
7 public aid cases recorded, with a total value of $2,177,505.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Oct 1, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | OIC Poland Fundacja Uniwersytetu Wsei | |
| Sep 23, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Marszałek Województwa Małopolskiego | |
| Dec 18, 2024 | Regional investment aid | –– | Marszałek Województwa Małopolskiego |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-10-01 | Research into the use of cell therapy to treat urinary system dysfunction in companion animals (female dogs) | $52,722$52,722 | European Funds for Małopolska 2021-2027 | |
| 2024-08-01 | Development of a globally innovative veterinary drug for chronic kidney disease in cats, based on allogeneic stem cells, and implementation of production under GMP pharmaceutical standards | $1.6M$1,601,017 | European Funds for Małopolska 2021-2027 | |
| 2024-07-01 | Purchase of infrastructure for conducting R&D on cell cultures under sterile conditions to develop globally innovative veterinary cell therapies | $468.5K$468,526 | European Funds for Małopolska 2021-2027 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Bioceltix S.A. | $616,315.97 | bioceltix.com | ||
| Famicordtx S.A. | $589,673.84 | famicordtx.com | ||
| Human Biome S.A. | $583,508.16 | human-biome.com | ||
| Animal Active sp. z o.o. | $546,374.91 | animalactive.pl | ||
| Forvite P.S.A. | $468,502.70 | forvite.com | ||
| Przychodnia Weterynaryjna Avi-Vet sp. z o.o. | $464,731.21 | avi-vet.pl | ||
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com | ||
| Multiqure S.A. | $284,781.52 | purebiologics.com | ||
| Bioactive-Tech sp. z o.o. | $228,068.15 | bioactivetech.pl | ||
| Nanosanguis S.A. | $192,701.50 | nanosanguis.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-08-05 | Share capital increase (61,050.00 PLN → 63,250.00 PLN) | |
| 2025-08-05 | Switch to PKD 2025 (7 PKD 2007 codes → 7 PKD 2025 codes) | |
| 2023-09-01 | Share capital increase (50,000.00 PLN → 61,050.00 PLN) | |
| 2023-03-21 | Entered in the register |
FAQ
Last updated: 2026-10-19